Search Result

Results for "

jak+inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (4) Autophagy (2) Drug Metabolite (1) Drug-Linker Conjugates for ADC (1) JAK (58) Reference Standards (5) STAT (8) TNF Receptor (1)
By Research Areas:	Cancer (22) Cardiovascular Disease (1) Infection (2) Inflammation/Immunology (36) Metabolic Disease (1) Neurological Disease (2)
Click Chemistry:	Alkynes (3)

Inhibitors & Agonists

Natural
Products

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-14435

Pyridone 6 Maximum Cited Publications 11 Publications Verification	JAK	Cancer
Pyridone 6 is a *pan-JAK* inhibitor, which potently inhibits the JAK kinase family, with IC₅₀s of 1 nM for JAK2 and TYK2, 5 nM for JAK3, and 15 nM for JAK1, while displaying significantly weaker affinities (130 nM to >10 mM) for other protein tyrosine kinases.

HY-109053

Delgocitinib 2 Publications Verification JTE-052	JAK	Inflammation/Immunology
Delgocitinib (JTE-052) is a specific *JAK* inhibitor with IC₅₀s of 2.8, 2.6, 13 and 58 nM for JAK1, JAK2, JAK3 and Tyk2, respectively .

HY-19568

Peficitinib Maximum Cited Publications 11 Publications Verification ASP015K; JNJ-54781532	JAK	Inflammation/Immunology
Peficitinib (ASP015K) is an orally active *JAK* inhibitor, with IC₅₀s of 3.9, 5.0, 0.7 and 4.8 nM for JAK1, JAK2, JAK3 and Tyk2, respectively .

HY-N2959

Brevilin A 5 Publications Verification	JAK STAT Apoptosis Autophagy	Cancer
Brevilin A is an orally active *STAT3/JAK* inhibitor (STAT3 IC₅₀=?10.6 μM). Brevilin A shows anti-tumor activity, anti-proliferative activity to cancer cells, and can induce apoptosis and autophagy .

HY-13577

Oclacitinib 4 Publications Verification PF-03394197	JAK	Inflammation/Immunology
Oclacitinib is a novel *JAK* inhibitor. Oclacitinib is most potent at inhibiting JAK1 (IC₅₀=10 nM).

HY-50856A

Ruxolitinib (S enantiomer) 3 Publications Verification S-Ruxolitinib; S-INCB18424	JAK	Cancer
Ruxolitinib (S enantiomer) (S-Ruxolitinib) is the S-enantiomer of Ruxolitinib (HY-50856). Ruxolitinib (S enantiomer) is an orally active, potent *JAK* inhibitor .

HY-13577A

Oclacitinib monomaleate 4 Publications Verification PF-03394197 monomaleate	JAK	Inflammation/Immunology
Oclacitinib maleate (PF-03394197 maleate) is a novel *JAK* inhibitor. Oclacitinib maleate (PF-03394197 maleate) is most potent at inhibiting JAK1 (IC₅₀=10 nM).

HY-132819

Ilunocitinib LY-3411067	JAK	Others
Ilunocitinib (compound 27) is a *JAK* inhibitor (extracted from patent WO2009114512A1) .

HY-136336

Tofacitinib metabolite-1 1 Publications Verification	Drug Metabolite	Others
Tofacitinib metabolite-1 is a metabolite of Tofacitinib, a JAK inhibitor. Tofacitinib metabolite-1 can be used in the pharmacokinetics and metabolism studies of tofacitinib .

HY-N3710

Dehydrocrenatidine Kumujian G; O-Methylpicrasidine I	JAK Apoptosis	Neurological Disease Cancer
Dehydrocrenatidine, a natural alkaloid, is a specific *JAK* inhibitor. Dehydrocrenatidine inhibits voltage-gated sodium channels and ameliorates mechanic allodia in a rat model of neuropathic pain .

HY-109148

Izencitinib TD-1473; JNJ-8398	JAK	Inflammation/Immunology
Izencitinib (TD-1473) is an orally active, non-selective and gut-restricted *JAK* inhibitor. Izencitinib (TD-1473) can be used in the study for ulcerative colitis .

HY-109182

Lorpucitinib JNJ-64251330	JAK STAT	Inflammation/Immunology
Lorpucitinib (JNJ-64251330) is an orally active *pan-JAK* inhibitor with good enteric selectivity and safety. Lorpucitinib can inhibit the JAK/STAT pathway and reduce the levels of inflammatory biomarkers in serum. Lorpucitinib can be used in the research of familial adenomatous polyposis and gastrointestinal inflammatory diseases .

HY-101024

PF-06263276	JAK STAT	Inflammation/Immunology
PF-06263276 (PF 6263276) is a potent and selective *pan-JAK* inhibitor, with IC₅₀s of 2.2 nM, 23.1 nM, 59.9 nM and 29.7 nM for JAK1, JAK2, JAK3 and TYK2, respectively. PF-06263276 inhibits pSTAT3 and TYK2 pathway. PF-06263276 has a protective effect against ear skin inflammation .

HY-148785

Nimucitinib	JAK	Others
Nimucitinib is a Janus kinase (JAK) inhibitor .

HY-19568R

Peficitinib (Standard) ASP015K (Standard); JNJ-54781532 (Standard)	Reference Standards JAK	Inflammation/Immunology
Peficitinib (Standard) is the analytical standard of Peficitinib. This product is intended for research and analytical applications. Peficitinib (ASP015K) is an orally active *JAK* inhibitor, with IC₅₀s of 3.9, 5.0, 0.7 and 4.8 nM for JAK1, JAK2, JAK3 and Tyk2, respectively .

HY-148791

Pumecitinib PG-011	JAK	Inflammation/Immunology Cancer
Pumecitinib is a Janus kinase (JAK) inhibitor. Pumecitinib shows anti-inflammatory activity .

HY-171366

lirucitinib	JAK	Inflammation/Immunology
lirucitinib is a *JAK* inhibitor, and has antiinflammatory activity. lirucitinib inhibits various itch- and inflammation-inducing cytokines that depend on JAK1 enzyme activity, as well as allergy-related cytokines. lirucitinib can be used for the study of pruritic skin diseases

HY-13961

GLPG0634 analog	JAK	Cancer
GLPG0634 analog (Compoun 176) is a broad spectrum *JAK* inhibitor with IC₅₀ values of <100 nM against JAK1, JAK2 and JAK3 .

HY-159536

Frevecitinib KN-002; VR-588	JAK	Inflammation/Immunology
Frevecitinib (KN-002) is a potent pan-JAK* inhibitor* (i.e. JAK1, JAK2, JAK3, TYK2). Frevecitinib can be used for the study of asthma and other respiratory conditions such as chronic obstructive pulmonary disease (COPD).

HY-143444

JAK-IN-20	JAK	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
JAK-IN-20 is a potent, pan and orally active *JAK* inhibitor with an IC₅₀s of 7 nM, 5 nM, 14 nM for JAK1, JAK2, JAK3, respectively. JAK-IN-20 shows excellent pharmacokinetics and displays anti-inflammatory efficacy in vivo .

HY-153440

Methyl 6-(1-(4-methoxybenzyl)-1H-pyrazol-4-yl)-4-oxo-4,5-dihydropyrazolo[1,5-a]pyrazine-2-carboxylate	JAK	Cancer
JAK-IN-25 (compound 19) is a potent *JAK* inhibitor with IC₅₀s of 6 nM, 21 nM, 8 nM, 1051 nM for TYK2, JAK1, JAK2, JAK3, respectively. JAK-IN-25 inhibits human whole blood IL-12 (HEB IL-12) with an IC₅₀ of 28 nM. JAK-IN-25 has the potential for cancer research .

HY-132849

Nezulcitinib TD-0903	JAK	Infection Inflammation/Immunology
Nezulcitinib (TD-0903) is an inhaled and lung-selective pan-Janus kinase (JAK) inhibitor. Nezulcitinib can be used for the research of COVID-19 associated acute lung injury and impaired oxygenation .

HY-19568B

Peficitinib hydrochloride ASP015K hydrochloride; JNJ-54781532 hydrochloride	JAK	Inflammation/Immunology
Peficitinib (ASP015K) hydrochloride is an orally active *JAK* inhibitor, with IC₅₀s of 3.9, 5.0, 0.7 and 4.8 nM for JAK1, JAK2, JAK3 and Tyk2, respectively .

HY-148060

JAK-IN-21 1 Publications Verification	JAK	Cancer
JAK-IN-21 (Example 4) is a selective and potent *JAK* inhibitor with IC₅₀s of 1.73, 2.04, 109 and 62.9 nM against JAK1, JAK2, J2V617F and TYK2, respectively .

HY-108342

PF-00956980	JAK	Inflammation/Immunology
PF-00956980 is a reversible pan-JAK* inhibitor* with IC₅₀ values of 2.2, 23.1 and 59.9 μM for JAK1, JAK2 and JAK3, respectively. PF-00956980 can be used in the research of lung and skin inflammatory diseases .

HY-19568A

Peficitinib hydrobromide ASP015K hydrobromide; JNJ-54781532 hydrobromide	JAK	Inflammation/Immunology
Peficitinib (ASP015K) hydrobromide is an orally active *JAK* inhibitor, with IC₅₀s of 3.9, 5.0, 0.7 and 4.8 nM for JAK1, JAK2, JAK3 and Tyk2, respectively .

HY-171242

LNK01004	JAK STAT	Others
LNK01004 is a *JAK* inhibitor with strong inhibitory effects on JAK1 (IC₅₀: 10 nM), JAK2 (IC₅₀:＜0.51 nM) and TYK2 (IC₅₀: 1.0 nM) . LNK01004 can simultaneously inhibit multiple cytokine-induced p-STAT signaling pathways. LNK01004 can be used in the research of diseases such as atopic dermatitis .

HY-107595

SD-1008 1 Publications Verification	JAK STAT Apoptosis	Cancer
SD-1008 is a potent *JAK* inhibitor. SD-1008 inhibits tyrosyl phosphorylation of STAT3, JAK2 and Src. SD-1008 also reduces STAT3-dependent luciferase activity. SD-1008 enhances apoptosis induced by Paclitaxel in ovarian cancer cells via directly blocking the JAK-STAT3 signaling pathway .

HY-14435R

Pyridone 6 (Standard)	JAK Reference Standards	Cancer
Pyridone 6 (Standard) is the analytical standard of Pyridone 6. This product is intended for research and analytical applications. Pyridone 6 is a pan-JAK inhibitor, which potently inhibits the JAK kinase family, with IC50s of 1 nM for JAK2 and TYK2, 5 nM for JAK3, and 15 nM for JAK1, while displaying significantly weaker affinities (130 nM to >10 mM) for other protein tyrosine kinases.

HY-153050

JAK-IN-24	JAK	Inflammation/Immunology Cancer
JAK-IN-24 is a *JAK* inhibitor, with IC₅₀s of 0.534 and 24 nM at the presence of 4 μM or 1mM ATP, respectively. JAK-IN-24 also inhibits PBMC IL-15 induced STAT5 phosphorylation with an IC₅₀ of 86.171 nM . JAK-IN-24 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-157011

JAK-IN-33	JAK	Inflammation/Immunology
JAK-IN-33 (compound 3 (R)) is a *JAK* inhibitor .

HY-154969

JAK-IN-29	JAK	Others
JAK-IN-29 (compound 3) is a potent JAK inhibitor .

HY-46262

JAK-IN-15	JAK	Cancer
JAK-IN-15 is a *JAK* inhibitor. WO2016119700A1 (Compound 15) .

HY-111749

JAK-IN-4	JAK	Inflammation/Immunology
JAK-IN-4 is a proagent of a *JAK* inhibitor, effective in murine collagen induced arthritis model .

HY-153712

JAK-IN-28	JAK	Inflammation/Immunology Cancer
JAK-IN-28 (Compound 111) is a *JAK* inhibitor. JAK-IN-28 can be used for research of cancer or inflammatory diseases .

HY-169758

CEE321	JAK	Inflammation/Immunology
CEE321 is a potent pan-JAK* inhibitor* with an IC₅₀ value of 54 nM. CEE321 potently inhibits biomarkers associated with atopic dermatitis .

HY-168984

Milpecitinib	JAK	Inflammation/Immunology Cancer
Milpecitinib (Compound 21a) is a potent, selective Janus tyrosine kinase (JAK) inhibitor with anti-inflammatory activity. Milpecitinib is promising for research of cancers and inflammatory disorders .

HY-111750

JAK-IN-3	JAK	Inflammation/Immunology
JAK-IN-3 (compound 22) is a potent *JAK* inhibitor, with IC₅₀ values of 3 nM, 5 nM, 34 nM and 70 nM for JAK3, JAK1, TYK2 and JAK2, respectively .

HY-109053A

Delgocitinib ethanolate JTE-052 ethanolate	JAK	Inflammation/Immunology
Delgocitinib ethanolate is a specific *JAK* inhibitor with IC₅₀s of 2.8, 2.6, 13 and 58 nM for JAK1, JAK2, JAK3 and Tyk2, respectively .

HY-167884

PF-1367550	JAK	Inflammation/Immunology
PF-1367550 is a pan-JAK* inhibitor*. PF-1367550 can decrease the levels of release of CXCL9, CXCL10 and CXCL11 from primary airway epithelial cells .

HY-18228

CP-352664	JAK	Inflammation/Immunology
CP-352664 is a *JAK* inhibitor. CP-352664 has a inhibitoinhibits JAK3 with an EC₅₀ value of 210 nM. CP-352664 is promising for research of organ transplant rejection and autoimmune disorders such as rheumatoid arthritis .

HY-151258

TK4g	JAK	Cancer
TK4g is a Janus kinase (JAK) inhibitor with the IC₅₀ values of 12.61 nM and 15.80 nM for JAK2 and JAK3, respectively. TK4g can be used in lymphoid-derived diseases and leukemia cancer research .

HY-156535

JAK kinase-IN-1	JAK	Inflammation/Immunology
JAK kinase-IN-1 (Example 1) is a *JAK* inhibitor. JAK kinase-IN-1 inhibits TYK2, JAK1, JAK2 and JAK3 with IC₅₀ values of 4.2 nM, 32 nM, 27 nM, 3473 nM respectively .

HY-153701

JAK-IN-26	JAK	Cancer
JAK-IN-26 (compound 2) is an orally active *JAK* inhibitor with good pharmacokinetic characteristics. JAK-IN-26 inhibits IFN-α2B-induced phosphorylation of STAT3 in Jurkat cells (IC₅₀=17.2 nM) .

HY-154994

JAK-IN-30	JAK	Inflammation/Immunology
JAK-IN-30 (compound 31) is a water-soluble *JAK* inhibitor with IC₅₀ values of 2, 15, 18 and 2 nM for JAK2, JAK1, JAK3 and TYK2, respectively. JAK-IN-30 has research potential for dry eye disease (DED) .

HY-U00277

JAK-IN-10	JAK	Inflammation/Immunology
JAK-IN-10 is a *JAK* inhibitor. JAK-IN-10 can be used for the research of dry eye disorders . JAK-IN-10 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-161621

JAK-IN-37	JAK	Inflammation/Immunology
JAK-IN-37 (Compound WU4) is a *JAK* inhibitor, with IC₅₀ values of 0.52, 2.26, 84 and 1.09 nM for JAK1, JAK2, JAK3 and JAK4, respectively. JAK-IN-37 can be used for the research of allogeneic hematopoietic cell transplantation (allo-HCT) .

HY-N2959R

Brevilin A (Standard)	Reference Standards JAK STAT Apoptosis Autophagy	Cancer
Brevilin A (Standard) is the analytical standard of Brevilin A. This product is intended for research and analytical applications. Brevilin A is an orally active STAT3/JAK inhibitor (STAT3 IC₅₀= 10.6 μM). Brevilin A shows anti-tumor activity, anti-proliferative activity to cancer cells, and can induce apoptosis and autophagy .

HY-U00318

JAK-IN-11	JAK	Inflammation/Immunology
JAK-IN-11 (Example 1,II) is a potent and selective *JAK* inhibitor. JAK-IN-11 has the potential for the skin disorders (such as cutaneous lupus) treatment . JAK-IN-11 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-156706

JAK-IN-31	JAK	Cancer
JAK-IN-31 (Example 75) is a *JAK* inhibitor with IC₅₀ ranges of ≤0.01µM, ≤0.01µM, 0.01-0.1 µM and ≤0.01µM for JAK1, JAK2, JAK3 and Tyk2 respectively. JAK-IN-31 can be used in cancer research .

Cat. No.	Product Name		Classification

HY-153050

JAK-IN-24		Alkynes
JAK-IN-24 is a *JAK* inhibitor, with IC₅₀s of 0.534 and 24 nM at the presence of 4 μM or 1mM ATP, respectively. JAK-IN-24 also inhibits PBMC IL-15 induced STAT5 phosphorylation with an IC₅₀ of 86.171 nM . JAK-IN-24 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-U00277

JAK-IN-10		Alkynes
JAK-IN-10 is a *JAK* inhibitor. JAK-IN-10 can be used for the research of dry eye disorders . JAK-IN-10 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-U00318

JAK-IN-11		Alkynes
JAK-IN-11 (Example 1,II) is a potent and selective *JAK* inhibitor. JAK-IN-11 has the potential for the skin disorders (such as cutaneous lupus) treatment . JAK-IN-11 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

jak+inhibitor

Inhibitors & Agonists

NaturalProducts

Click Chemistry

Natural
Products